Dynavax Technologies | DVAX - Current Liabilities



Dynavax Technologies reported $118.23M in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
AbbVie USD 36.4B 2.35B Mar/2025
Adma Biologics USD 74.94M 19.4M Jun/2025
Amgen USD 20.48B 2.53B Jun/2025
AstraZeneca USD 33.54B 4.41B Jun/2025
Biogen USD 3.18B 2.11B Jun/2025
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
Bristol-Myers Squibb USD 27.53B 3.46B Jun/2025
Dynavax Technologies USD 118.23M 49.85M Jun/2025
Gilead Sciences USD 11.19B 1.15B Jun/2025
Glaxosmithkline GBP 20.38B 1.32B Jun/2025
Merck USD 26.04B 863M Jun/2025
Neurocrine Biosciences USD 546.3M 23.4M Jun/2025
Novartis USD 31.71B 95M Jun/2025
Pfizer USD 37.73B 1.27B Jun/2025
Regeneron Pharmaceuticals USD 3.67B 100.4M Jun/2025
Roche Holding CHF 27.02B 424M Dec/2024
Sarepta Therapeutics USD 919.95M 314.36M Jun/2025
TG Therapeutics USD 171.89M 11.68M Jun/2025
Vertex Pharmaceuticals USD 4.14B 355.2M Jun/2025